For the latest COVID-19 Travel restrictions and recommendations please click here

SMi present their 17th annual conference on

European Pharmaceutical Pricing & Reimbursement

31st October – 1st November 2011
Basel, Switzerland

2011 has brought with it huge changes to the health care landscape - the global economic crisis and rising healthcare costs have caused governments to take cautious approaches towards pricing and reimbursement (P&R) for pharmaceuticals.

With aging and expanding populations, improving standards of living has meant there has been a significant burden on the healthcare systems. Emerging markets are also finding it challenging to meet the increasing expectations for healthcare, despite rapid economic growth. This event will therefore review the key challenges and developments in the emerging markets, established markets and the US with their impact on international healthcare

Key topics include: 

  • EU Policy challenges in access to medicine in Europe
  • HTA agency policy and practice globally: Comparing and contrasting different models
  • Germany's AMNOG: Facts and consequences              
  • Lessons learnt from international experience of VBP
  • The access marketing mix for launch products
  • Orphan drug P&R in Europe: Are the payors biting back?


 Executives in the following areas:

  • Market Access
  • Launch Excellence
  • Pricing and Reimbursement
  • Marketing (Consumer, Relationship, Multi channel,Strategic)
  • Project Management
  • Value Based Pricing
  • Business Development
  • Patient Advocacy
  • Medical Information & Education
  • CRM
  • Business Analysis
  • eMarketing
  • Pharmacy Operations
  • Specialty and Orphan drugs market
  • Patient communications
  • Health economics and outcomes research
  • External affairs


Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Donald Macarthur

Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

9:10 Pricing in Germany with new AMNOG

Markus Jahn

Markus Jahn, Manager, Pricing, Novartis Pharma GmbH

• Benefit assessment of launch drugs and in-market brands
• Pricing roadmap after benefit assessment - fixed price or central price-negotiation
• First experiences with the new regulation and outlook

9:50 Germanys AMNOG: Facts and consequences

Frank Thoss

Frank Thoss, Lawyer, Strategic Policy Affairs, German Association of Research-Based Pharmaceutical Companies

• Regulation of the German pharmaceutical market before AMNOG before Jan 1st 2011
• AMNOG-process of early benefit assessment and central price-negotiations in detail
• First experiences with the new regulation
• Possible consequences for other countries


10:30 Morning Coffee

10:50 AMNOG – Procedural Challenges and First Lessons Learned

Bernd Bruggenjurgen

Bernd Bruggenjurgen, Managing Director, Boston Healthcare Associates

Being prepared – Internal Planning and External Communications with G-BA
Major Challenge - the Choice of the Comparator
Issues in Costing Information
Implication on data requirements – is there any need in longitudinal data?

11:30 New realities and new approaches

Cath West

Cath West, Consultant, Inpharmation

Pricing and market access in Europe is undergoing revolutionary change.
However, the industry model for pricing research (qualitative research with ex-payers and technical advisors to payers etc.) is not undergoing corresponding changes.
This means that pricing research is now a "lagging indicator" and is seriously "behind the curve".
What approaches work best when industries are facing revolutionary change and how does this apply to pharma?

12:10 Networking Lunch

13:30 Orphan Drug P&R in Europe: Are the payers biting back?

Donald Macarthur

Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

• Situation with approved orphan drugs in EU-5
• Vital role of funding
• What payers won't buy
• How and where HTA limits access
• Successful company strategies

14:10 Panel Discussion

15:00 Afternoon Tea

15:20 Market Access to Orphan Drugs in Italy

Laura Crippa

Laura Crippa, Director, Market Access and pricing, Temas Srl

• Mechanisms for “early reimbursement” of orphan drugs
• The pricing and reimbursement process for orphan drugs
• Orphan drugs and innovation

16:00 Change Drivers in pricing and reimbursement practice

Jorge Wernli

Jorge Wernli, Vice President, Vifor Pharma

• Changing macroeconomic environment – countries under economic pressure
• Envolving stakeholder roles – the patient
• P&R evaluation price setting and reimbursement mechanisms
• Increased use of generics and similar - perceptions

16:40 Chairman’s Closing Remarks and Close of Day One

Donald Macarthur

Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Neil Palmer

Neil Palmer, President and Principal Consultant, PDCI Market Access Inc. Formerly RTI Health Solutions

9:10 Value based pricing - Principles and practice in the UK policy context

Martina Garau

Martina Garau, Economist, Office Of Health Economics

  • Approaches to value base pricing (VBP)
  • Lessons learnt from international experience of VBP
  • Introducing VBP in  the UK:
  • The Department of Health consultation
  • How might VBP be implemented and what are the expected consequences?
  • 9:50 Market access in European Established Markets

    Isabel Henkel

    Isabel Henkel, Director Access & Reimbursement , Johnson & Johnson Ethicon

    • Overview of key stakeholders in Europe’s established markets
    • Who are the key agencies in the market
    • Understanding HTA regulations in Europe

    10:30 Morning Coffee

    11:00 Market access in emerging markets

    Henderson Azevedo

    Henderson Azevedo, Head of Pricing, Tender and Institutional Business , Novartis Group Emerging Markets

    • Recent developments and future trends
    • Opportunities and threats - a pharmaceutical industry perspective
    • Lessons from developed markets

    11:40 Canadian Market Access Update

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access Inc. Formerly RTI Health Solutions

    • Overview of Canadian health care system and pharmaceutical funding
    • Price regulation and the new Patented Medicine Prices Review Board (PMPRB) guidelines
    • CADTH - Common Drug Review (CDR), pCODR (oncology drugs), INESSS (Quebec), provincial and private reimbursement schemes
    • Implications of the Ontario 25% pricing rule for generics and the evolution of Product Listing Agreements (PLAs)
    • Outlook for Canadian pricing & reimbursement

    12:20 Networking Lunch

    13:50 The patient’s role in market access in public healthcare systems

    Bertram Häussler

    Bertram Häussler, Director, IGES Institut.

    • Increasing patient choices in an equitable way
    • Patient-reported outcome measures
    • Achieving maximum levels of patient and market access

    14:30 The access marketing mix for launch products

    Jan Posthumus

    Jan Posthumus, Head of Global Market Access and Market Research, Basilea Pharmaceutica

    • Access marketing for the different stakeholders
    • Preparation for launch from an access perspective: timelines, tools and techniques

    15:10 Latest regulations within pricing and reimbursement

    Mark Powell

    Mark Powell, Partner, White and Case

    • EU initiatives in pricing and reimbursement
    • Risk Sharing Agreements
    • Patient Access Schemes

    15:50 Chairman’s Closing Remarks and Close of Day Two

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access Inc. Formerly RTI Health Solutions

    16:00 Afternoon Tea



    Cooperation with Payors as a Means for Attaining Reimbursement

    Cooperation with Payors as a Means for Attaining Reimbursement

    Radisson Blu Hotel Basel
    2nd November 2011
    Basel, Switzerland

    Radisson Blu Hotel Basel

    Steinentorstrasse 25
    Basel CH-4001

    Radisson Blu Hotel Basel



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out